Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR1E | P28566 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ortetamine SCHEMBL29388899 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL27660676 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL3460028 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL42180 | 1.00 | TAAR1 (0.52) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL16737004 | 0.98 | TAAR1 (0.50) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL744048 | 0.98 | TAAR1 (0.50) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL4381142 | 0.90 | SLC6A4 (0.70) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL2857779 | 0.85 | SLC6A2 (0.61) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| Ortetamine SCHEMBL27703116 | 0.83 | CYP2D6 (0.44) | TAAR1SLC6A2SLC6A4SLC6A3MAOA | |
| SCHEMBL727640 | 0.83 | SOS2 (0.53) | TAAR1SLC6A2SLC6A4SLC6A3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069546-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | VIVUS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20240366513-A1 | Methods For Administering Weight Loss Medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-11-07 | — | — | US | disclosed |
| US-12048769-B2 | Methods for administering weight loss medications | NALPROPION PHARMACEUTICALS LLC (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230301922-A1 | Layered Pharmaceutical Formulations | NALPROPION PHARMACEUTICALS LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230225981-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | AMERICAN ENTERTAINMENT PROPERTIES CORP., AS LENDER | 2023-07-20 | — | — | US | disclosed |
| US-20210378972-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | VIVUS LLC | 2021-12-09 | — | — | US | disclosed |
| US-20200352863-A1 | Methods For Administering Weight Loss Medications | Naipropion Pharmaceuticals LLC (US) | 2020-11-12 | — | — | US | disclosed |
| US-20200188313-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | VIVUS LLC (F/K/A VIVUS, INC.) | 2020-06-18 | — | — | US | disclosed |
| US-20190350866-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | VIVUS, INC. | 2019-11-21 | — | — | US | disclosed |
| US-20190282503-A1 | Methods For Administering Weight Loss Medications | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2019-09-19 | — | — | US | disclosed |
| US-20110059170-A1 | METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS | OREXIGEN THERAPEUTICS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100215739-A1 | LOW DOSE TOPIRAMATE / PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | VIVUS LLC (F/K/A VIVUS, INC.) | 2010-08-26 | — | — | US | disclosed |
| EP-2089005-B1 | LAYERED PHARMACEUTICAL FORMULATIONS COMPRISING AN INTERMEDIATE RAPIDLY DISSOLVING LAYER | OREXIGEN THERAPEUTICS INC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009152189-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSTION AND METHODS OF USE THEREOF | VIVUS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-2088998-A2 | UNIT DOSAGE PACKAGE AND METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS | Orexigen Therapeutics, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2089005-A2 | LAYERED PHARMACEUTICAL FORMULATIONS COMPRISING AN INTERMEDIATE RAPIDLY DISSOLVING LAYER | Orexigen Therapeutics, Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008060963-A2 | LAYERED PHARMACEUTICAL FORMULATIONS COMPRISING AN INTERMEDIATE RAPIDLY DISSOLVING LAYER | OREXIGEN THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008060964-A2 | UNIT DOSAGE PACKAGE AND METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS | OREXIGEN THERAPEUTICS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080113026-A1 | LAYERED PHARMACEUTICAL FORMULATIONS | OREXIGEN THERAPEUTICS, INC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080110792-A1 | METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS | OREXIGEN THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210378972-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | HTR3A, TPH1, HTR1B | TAAR1 117/4885SLC6A2 23/4885SLC6A4 32/4885 |
| US-20100215739-A1 | LOW DOSE TOPIRAMATE / PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | HTR3A, TPH1, HTR1B | TAAR1 117/4885SLC6A2 23/4885SLC6A4 32/4885 |
| US-20260069546-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | HTR1B, SLC6A2, HTR2B | TAAR1 51/4885SLC6A2 2/4885SLC6A4 6/4885 |
| US-20230225981-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | HTR3A, TPH1, HTR1B | TAAR1 117/4885SLC6A2 23/4885SLC6A4 32/4885 |
| US-20200188313-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | HTR3A, TPH1, HTR1B | TAAR1 117/4885SLC6A2 23/4885SLC6A4 32/4885 |
| US-20190350866-A1 | LOW DOSE TOPIRAMATE/PHENTERMINE COMPOSITION AND METHODS OF USE THEREOF | HTR3A, TPH1, HTR1B | TAAR1 117/4885SLC6A2 23/4885SLC6A4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.